ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0826

Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study

Paul Emery1, Yoshiya Tanaka2, Vivian Bykerk3, Clifton Bingham III4, Thomas Huizinga5, Gustavo Citera6, Kuan-Hsiang Gary Huang7, Sean Connolly8, Yedid Elbez9, Robert Wong8, Karissa Lozenski8 and Roy Fleischmann10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Hospital for Special Surgery, New York, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, 8Bristol-Myers Squibb Company, Princeton, NJ, 9Excelya, Boulogne-Billancourt, France, 10Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

Meeting: ACR Convergence 2020

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Biologicals, clinical trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In the 56-week (wk) induction period (IP) of the Phase IIIb Assessing Very Early RA Treatment (AVERT)-2 trial (NCT02504268), a greater proportion of patients (pts) achieved SDAI remission (≤3.3) with SC abatacept (ABA) 125 mg once weekly (QW) + MTX vs ABA placebo (PBO) + MTX.1 Of pts who achieved sustained SDAI remission in the IP and completed a subsequent 48-wk de-escalation (DE) period, ~50% had maintained remission at DE Wk 48.2 However, whether pts were in sustained remission throughout the DE period is not known. This analysis evaluated pt flow during the DE period.

Methods: Pts who met the inclusion criteria (age ≥18 years [yrs]; RA diagnosis [ACR/EULAR 2010 criteria]; RA duration ≤6 months; SDAI >11; ACPA+; elevated CRP >3 mg/L or ESR ≥28 mm/h; TJC ≥3 and SJC ≥3; DMARD naïve) were enrolled in the 56-wk IP of AVERT-2 and received 1 yr of blinded treatment with ABA QW + MTX or ABA PBO + MTX. Pts who completed induction with ABA + MTX and had sustained SDAI remission (≤3.3 at both Wks 40 and 52 of the 56-wk IP) entered the DE phase and were re-randomized 1:1:1 to ABA QW + MTX for 48 wks (ABA continuation), ABA every other wk (EOW) + MTX for 24 wks then ABA PBO + MTX for 24 wks (DE/withdrawal), or ABA QW + MTX PBO for 48 wks (ABA monotherapy). Pts in sustained SDAI remission on ABA PBO + MTX during the IP were not re-randomized and continued the same blinded treatment in the DE phase (MTX monotherapy). MTX and oral CS doses were maintained in the DE period. Proportion of pts in each SDAI disease activity category (remission, low, moderate, high) was assessed over time (intent-to-treat analysis). Flow of disease activity to DE Wk 48, among re-randomized patients, was plotted using Sankey diagrams.

Results: The proportion of pts with high disease activity at IP baseline, by DE treatment arm, ranged from 72% to 76% for ABA + MTX-treated pts (DE re-randomization). Among pts who had achieved sustained SDAI remission in the IP, at the start of the DE period, 147 ABA + MTX-treated pts were re-randomized to ABA continuation (n=50), DE/withdrawal (n=50) or ABA monotherapy (n=47), and 37 pts assigned MTX monotherapy during the IP continued treatment in the DE period. During the DE period, fewer changes in disease activity were seen with ABA continuation versus DE/withdrawal or ABA monotherapy. The proportions of patients in SDAI remission were: ABA continuation: 72% at Wk 0, 74% at Wk 48 (Figure 1); ABA DE/withdrawal: 88% at Wk 0, 74% at Wk 24 for ABA EOW + MTX and 48% at Wk 48 after ABA withdrawal (Figure 2); ABA monotherapy: 77% at Wk 0, 57% at Wk 48 (Figure 3).

Conclusion: Fewer changes in disease activity were observed when IP treatment was maintained during the DE period. Most pts with high disease activity at IP baseline who achieved SDAI remission sustained remission during the DE period, suggesting that DE is possible once sustained remission has been achieved. Continued treatment with abatacept QW + MTX provided the best outcome.

References

  1. Emery P, et al. Arthritis Rheumatol 2018;70(suppl 10):602–604.
  2. Emery P, et al. Arthritis Rheumatol 2019;71(suppl 10):5241–5242.

Medical writing: Lola Parfitt (Caudex)


Disclosure: P. Emery, AbbVie, 2, 8, Bristol-Myers Squibb Company, 2, 8, Pfizer, 8, Roche, 2, 8, Celltrion, 8, Eli Lilly, 8, Gilead, 8, Novartis, 2, 8, Samsung, 8; Y. Tanaka, AbbVie, 2, 5, 8, UCB, 2, 5, 8, Sanofi, 2, 5, 8, Asahi-kasei, 2, 5, 8, Novartis, 2, 5, 8, GlaxoSmithKline, 2, 5, 8, Astellas, 2, 5, 8, Chugai, 2, 5, 8, Daiichi-Sankyo, 2, 5, 8, Eisai, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead Sciences, Inc., 2, 5, 8, Janssen, 2, 5, 8, Mitsubishi-Tanabe, 2, 5, 8, Pfizer, 2, 5, 8, Takeda, 2, 5, 8, YL Biologics, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8; V. Bykerk, Amgen, 2, 5, UCB, 5, National Institute of Health, 2, 9, Bristol-Myers Squibb Company, 2, 5, Gilead, 5, Pfizer, 5, Brainstorm Therapeutics, 1, 3; C. Bingham III, Bristol-Myers Squibb, 2, 5, 8, Genetech, 5, 8, Sanofi, 5, 8, AbbVie, 5, Eli Lilly, 5, Pfizer, 5, Gilead Sciences, Inc., 5, Regeneron, 5; T. Huizinga, Bristol-Myers Squibb Company, 2, 8, Pfizer, 2, 8, Eli Lilly, 2, 8, LUMC, 9; G. Citera, AbbVie, 5, 8, Eli Lilly, 5, 8, Bristol-Myers Squibb Company, 5, 8, Gema, 5, 8, Pfizer, 5, 8, Janssen, 5, 8; K. Huang, Bristol-Myers Squibb Company, 1, 3, 4; S. Connolly, Bristol-Myers Squibb Company, 1, 3, 4; Y. Elbez, Bristol-Myers Squibb Company, 9; R. Wong, Bristol-Myers Squibb Company, 1, 3, 4; K. Lozenski, Bristol-Myers Squibb Company, 3; R. Fleischmann, Pfizer, 2, 5.

To cite this abstract in AMA style:

Emery P, Tanaka Y, Bykerk V, Bingham III C, Huizinga T, Citera G, Huang K, Connolly S, Elbez Y, Wong R, Lozenski K, Fleischmann R. Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-responses-and-patient-flow-over-2-years-of-treatment-with-abatacept-including-dose-de-escalation-in-patients-with-early-mtx-naive-acpa-ra-results-from-a-phase-iiib-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-responses-and-patient-flow-over-2-years-of-treatment-with-abatacept-including-dose-de-escalation-in-patients-with-early-mtx-naive-acpa-ra-results-from-a-phase-iiib-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology